title: Prognostic value of stress 99mTc-tetrofosmin myocardial perfusion imaging in predicting all-cause mortality: a 6-year follow-up study.
abstract: OBJECTIVE
  The aim of this study was to ascertain whether stress myocardial perfusion imaging can independently predict long-term mortality.
  
  
  METHODS
  We studied 1,386 patients with known or suspected coronary artery disease by means of stress 99mTc-tetrofosmin myocardial perfusion tomography. The end point during follow-up was death from any cause. Mortality rates were compared with that in a reference population using calculated age- and gender-specific data in the general population.
  
  
  RESULTS
  Mean age was 60+/-11 years. There were 608 (44%) women. Perfusion abnormalities were fixed in 416 (30%) patients and reversible in 445 (32%) patients. During a mean follow-up of 6+/-1.9 years, 290 (21%) patients died. The annual mortality was 1.7% in patients with normal perfusion and 5.2% in patients with abnormal perfusion. Patients with multivessel distribution of perfusion abnormalities had the highest annual mortality (6.2%). The annual mortality in the reference population was 3.2%. In a multivariate analysis model, predictors of death were age [risk ratio (RR)=1.06, 95% CI 1.04-1.07], male gender (RR=2, CI 1.6-2.6), history of heart failure (RR=2.3, CI 1.8-3.1), diabetes mellitus (RR=2.1, CI 1.6-2.7), smoking (RR=1.8, CI 1.4-2.3), reversible perfusion defects (RR=1.8, CI 1.4-2.5) and fixed perfusion defects (RR=1.7, CI 1.3-2.1).
  
  
  CONCLUSIONS
  Myocardial perfusion abnormalities on stress 99mTc-tetrofosmin tomography are independently associated with long-term risk of death. The extent of perfusion abnormalities is a major determinant of mortality. The presence of normal perfusion is associated with a lower mortality compared with the general population.
authors.affiliation: Thoraxcenter, Department of Cardiology, University Hospital Dijkzigt, Rotterdam, The Netherlands. Aelhendy@unmc.edu
authors.forename: Abdou
authors.initials: A
authors.lastname: Elhendy
authors.forename: Arend F L
authors.initials: AF
authors.lastname: Schinkel
authors.forename: Ron T
authors.initials: RT
authors.lastname: van Domburg
authors.forename: Jeroen J
authors.initials: JJ
authors.lastname: Bax
authors.forename: Roelf
authors.initials: R
authors.lastname: Valkema
authors.forename: Elena
authors.initials: E
authors.lastname: Biagini
authors.forename: Don
authors.initials: D
authors.lastname: Poldermans
mesh_terms: D003324:Coronary Artery Disease / Q000000981:diagnostic imaging* / Q000401:mortality*; D005080:Exercise Test / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D010477:Perfusion / Q000706:statistics & numerical data; D015995:Prevalence; D011379:Prognosis; D016016:Proportional Hazards Models; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D015996:Survival Rate; D014665:Vasodilator Agents
chemical_list: D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D014665:Vasodilator Agents; C078700:technetium tc-99m tetrofosmin